Julian Schardt

Konsensusempfehlungen für Cancer Survivorship Care in der Schweiz

Manuela Eicher, Eva Maria Tinner, Sacha I. Rothschild, Nicolas Sperisen et autres

Mit der wachsenden Zahl von Menschen, die eine Krebserkrankung überleben, rückt die Bedeutung einer strukturierten und qualitativ hochwertigen Survivorship Care zunehmend in den Vordergrund. Während die Primärtherapie in der Regel eng begleitet wird, können nach deren Abschluss Versorgungslücken bestehen. Diese betreffen nicht …

Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial

Sarah Farag, Ulrike Bacher, Barbara Jeker, Myriam Legros et autres

Abstract Definite cure remains exceptional in myeloma patients even after high-dose chemotherapy (HDCT) with melphalan (Mel) and autologous stem cell transplantation (ASCT). Thus, improving efficacy of HDCT in MM remains an unresolved issue. This randomized phase II trial compared standard 200 mg/m2 …

ch (code pays fourni par la source)

Long lasting response to anti-PD-1 therapy of recurrent conjunctival squamous cell carcinoma - A case report and systematic review of the literature

Michèle J. Hoffmann, Julian Schardt, C Ionescu, Ute Wolf-Schnurrbusch et autres

Squamous cell carcinoma (SCC) are slowly progressing tumors which represent the most common malignancy of the ocular surface. The standard of care is surgical excision with wide margins combined with intra-operative cryotherapy. In advanced disease, ocular enucleation or orbital exenteration is recommended. …

ch (code pays fourni par la source)

Safety and efficacy of perioperative cisplatin/gemcitabine (cis/gem) and durvalumab (durva) for operable muscle-invasive urothelial carcinoma (MIUC): SAKK 06/17.

Richard Cathomas, Sacha I. Rothschild, Stefanie Hayoz, Martin Spahn et autres

430 Background: The combination of cisplatin-based chemotherapy with immune checkpoint inhibitors is extensively investigated in urothelial carcinoma. Using this combination in the neoadjuvant setting for patients (pts) with MIUC might improve pathological response rate (PaR: 1 EFS at 2 years ≥ 65% …

ch (code pays fourni par la source)

353 Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC

Antonio Jimeno, Sophie Papa, Missak Haigentz, Juan Francisco Rodríguez-Moreno et autres

Background Single agent checkpoint inhibitors (CPI) are an approved first or second-line therapy in head and neck squamous cell carcinoma (HNSCC), but their efficacy is limited. Adoptive cell therapy with tumor infiltrating lymphocytes (TIL, LN-145) has demonstrated efficacy in multiple malignancies alone …

us, gb, es, ch (code pays fourni par la source)

Der Einsatz von Immuncheckpoint-Inhibitoren im onkologischen Alltag

Julian Schardt

BACKGROUND: The advent of immune checkpoint inhibitors has dramatically changed the treatment landscape of many different tumor types. In the clinical routine, humanized antibodies against the immune checkpoints cytotoxic T‑lymphocyte associated protein 4 (CTLA-4) and programmed cell death 1/programmed cell death ligand …

ch, at (code pays fourni par la source)

716P Optimizing ipilimumab in metastatic renal cell carcinoma: SAKK 07/17 study

Frank Stenner, Richard Cathomas, Christian Rothermundt, Julian Schardt et autres

ch, gb (code pays fourni par la source)

Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice

Richard Cathomas, Julian Schardt, Miklos Pless, Anna Lladó et autres

AIMS OF THE STUDY: Atezolizumab is an approved therapy for urothelial carcinoma based on results from the IMvigor 210 and IMvigor211 phase II and III trials. The global SAUL study evaluated atezolizumab in a broader patient population more representative of real-world populations. …

ch (code pays fourni par la source)

Perioperative chemoimmunotherapy with durvalumab (Durva) in combination with cisplatin/gemcitabine (Cis/Gem) for operable muscle-invasive urothelial carcinoma (MIUC): Preplanned interim analysis of a single-arm phase II trial (SAKK 06/17).

Richard Cathomas, Ulf Petrausch, Stefanie Hayoz, Martina Schneider et autres

499 Background: Cisplatin-based neoadjuvant chemotherapy followed by surgery is the standard of care for patients (pts) with MIUC but relapse rates remain high. Immune checkpoint inhibitors have demonstrated efficacy in advanced urothelial carcinoma (UC). We hypothesize that the integration of the PD-L1 …

ch, de (code pays fourni par la source)

Immuntherapie – Übersicht, Wirkmechanismen, Anwendung

Ruben Bill, Julian Schardt

Zusammenfassung. Die Entwicklung von neuen Immuntherapien hat die Behandlungskonzepte von unterschiedlichen Krebsarten aus der Reihe der soliden Tumoren bis hin zu hämatologischen Krebserkrankungen in den letzten Jahren revolutioniert. Dabei werden in der klinischen Routine vor allem sogenannte Immuncheckpoint-Inhibitoren (ICI) eingesetzt. Immuncheckpoints wie …

ch, at (code pays fourni par la source)

Solid cancer development in solid organ transplant recipients within the Swiss Transplant Cohort Study

Emanuel Lengwiler, Susanne Stampf, Alfred Zippelius, Emanuela Salati et autres

In solid organ transplant recipients (sOTRs), 5 years after transplantation cancer is a relevant cause of death. We aimed to report cancer incidence in the Swiss Transplant Cohort Study (STCS) between 2008 and 2014 and conducted a prospective cohort study of kidney, …

ch (code pays fourni par la source)

Abstract P1-18-01: Incidence of hypocalcemia in patients with metastatic breast cancer under treatment with denosumab: A non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every 4 weeks versus every 12 weeks: SAKK 96/12 (REDUSE)

AMANDA OLGA MÜLLER, AJ Templeton, Stefanie Hayoz, Hanne Hawle et autres

Abstract Background Monthly Denosumab (DN) has shown superiority over zoledronic acid (ZA) in delaying skeletal related events. Randomized trials have shown that ZA given every 12 weeks (q12w) is non-inferior to ZA given every 4 weeks (q4w). The primary endpoint of the …

ch (code pays fourni par la source)